ImmunoPrecise Announces Results of Annual General Meeting

IMMUNOPRECISE ANTIBODIES today anounces that Paul Andreola has been appointed as the 6th director of the Company.


Immunoprecise Antibodies expands its services

IMMUNOPRECISE ANTIBODIES expands its services, anounces settlement agreement with Crossbeta Biosciences BV and announces a dept settlement.


ModiQuest to Offer Ligand's Omni-Ab Service in Europe

IMMUNOPRECISE ANTIBODIES today announces that ModiQuest® Research is now an OmniAb approved CRO.


ImmunoPrecise Antibodies collaborates with Top15 Pharmaceutical company.

IMMUNOPRECISE ANTIBODIES today initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company.


ImmunoPrecise Announces Phage Display-Based Antibody Discovery Platforms.

IMMUNOPRECISE ANTIBODIES announced the addition of in-house and custom scFv and VHH phage libraries to their growing service offerings through recent expansion in Europe.


IMMUNOPRECISE ANTIBODIES’ Q1 REVENUES INCREASE 386% OVER Q1 2017.

IMMUNOPRECISE ANTIBODIES today reports its financial results for Q1 ended July 31, 2018. The financial statements and related management’s discussion and analysis (“MD&A”) can be viewed on (www.cdrd.ca).

Items 1 to 6 of 48 total

Show per page